ABIONYX Pharma: Review of the first quarter of 2026

ABIONYX Pharma announced revenue of €0.8 million for the first quarter of 2026, down from 2025. The biopharmaceutical company leverages its proprietary apoA-I-based technology platform to develop innovative therapies. No revenue is generated from its core business, as its products are offered under a compassionate access program. Cash and cash equivalents remained stable at €2.8 million as of March 31, 2026.

The company has secured financing through a capital increase and a non-dilutive loan, guaranteeing its financial stability until the end of 2028. This financing will support the development of CER-001 for orphan deficiencies and a Phase 2b clinical trial in sepsis.